Keywords
Last Name
Institution

DOUGLAS D BOYD

TitleProfessor
InstitutionMD Anderson
DepartmentCancer Biology
Address7777 Knight Rd
Houston TX 77054-3005
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Boyd DD, Macchiarella ND. Occupant Injury Severity and Accident Causes in Helicopter Emergency Medical Services (1983-2014). Aerosp Med Hum Perform. 2016 Jan; 87(1):26-31. PMID: 26735230.
      View in: PubMed
    2. Boyd DD, Stolzer A. Accident-precipitating factors for crashes in turbine-powered general aviation aircraft. Accid Anal Prev. 2016 Jan; 86:209-16. PMID: 26590507.
      View in: PubMed
    3. Boyd DD, Peters C. Should Charity Air Medical Organizations Require Commercial Certification of Their Pilots? Air Med J. 2015 Jul-Aug; 34(4):188-94. PMID: 26206543.
      View in: PubMed
    4. Boyd DD. Occupant injury and fatality in general aviation aircraft for which dynamic crash testing is certification-mandated. Accid Anal Prev. 2015 Jun; 79:182-9. PMID: 25838192.
      View in: PubMed
    5. Boyd DD. Causes and risk factors for fatal accidents in non-commercial twin engine piston general aviation aircraft. Accid Anal Prev. 2015 Apr; 77:113-9. PMID: 25701648.
      View in: PubMed
    6. Shao BS, Guindani M, Boyd DD. Causes of fatal accidents for instrument-certified and non-certified private pilots. Accid Anal Prev. 2014 Nov; 72:370-5. PMID: 25118128.
      View in: PubMed
    7. Shao BS, Guindani M, Boyd DD. Fatal accident rates for instrument-rated private pilots. Aviat Space Environ Med. 2014 Jun; 85(6):631-7. PMID: 24919384.
      View in: PubMed
    8. Boyd D, Wetterneck C, Hart J. Potential utility of full motion flight simulators for treatment of individuals with a fear of flying. Aviat Space Environ Med. 2013 Mar; 84(3):264-5. PMID: 23513291.
      View in: PubMed
    9. Chauhan S, Goodwin JG, Chauhan S, Manyam G, Wang J, Kamat AM, Boyd DD. ZKSCAN3 is a master transcriptional repressor of autophagy. Mol Cell. 2013 Apr 11; 50(1):16-28. PMID: 23434374; PMCID: PMC3628091.
    10. Kim J, Ebertowski J, Janiga M, Arzola J, Gillespie G, Fountain M, Soderdahl D, Canby-Hagino E, Elsamanoudi S, Gurski J, Davis JW, Parker PA, Boyd DD. Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance. BJU Int. 2013 May; 111(6):934-40. PMID: 23350937; PMCID: PMC3637421.
    11. Rogers D, Boyd DD, Fox EE, Cooper S, Goldhagen M, Shen Y, Del Junco DJ. Prostate cancer incidence in U.S. Air Force aviators compared with non-aviators. Aviat Space Environ Med. 2011 Nov; 82(11):1067-70. PMID: 22097644; PMCID: PMC3250083.
    12. Chauhan S, Boyd DD. Regulation of u-PAR gene expression by H2A.Z is modulated by the MEK-ERK/AP-1 pathway. Nucleic Acids Res. 2012 Jan; 40(2):600-13. PMID: 21937508; PMCID: PMC3258129.
    13. del Junco DJ, Fox EE, Cooper S, Goldhagen M, Koda E, Rogers D, Canby-Hagino E, Kim J, Pettaway C, Boyd DD. Increasing low risk prostate cancer incidence in United States Air Force servicemen and selection of treatments. J Urol. 2011 Jun; 185(6):2137-42. PMID: 21496842; PMCID: PMC3171171.
    14. Avila H, Wang H, Chauhan S, Hartig S, Boyd DD. Accelerated urokinase-receptor protein turnover triggered by interference with the addition of the glycolipid anchor. Biochem J. 2011 Mar 1; 434(2):233-42. PMID: 21143195.
      View in: PubMed
    15. Mo P, Wang H, Lu H, Boyd DD, Yan C. MDM2 mediates ubiquitination and degradation of activating transcription factor 3. J Biol Chem. 2010 Aug 27; 285(35):26908-15. PMID: 20592017.
      View in: PubMed
    16. Ishiguro T, Avila H, Lin SY, Nakamura T, Yamamoto M, Boyd DD. Gene trapping identifies chloride channel 4 as a novel inducer of colon cancer cell migration, invasion and metastases. Br J Cancer. 2010 Feb 16; 102(4):774-82. PMID: 20087350.
      View in: PubMed
    17. Yang L, Zhang L, Wu Q, Boyd DD. Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets. J Biol Chem. 2008 Dec 12; 283(50):35295-304. PMID: 18940803.
      View in: PubMed
    18. Yang L, Hamilton SR, Sood A, Kuwai T, Ellis L, Sanguino A, Lopez-Berestein G, Boyd DD. The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. Cancer Res. 2008 Jun 1; 68(11):4321-30. PMID: 18519692.
      View in: PubMed
    19. Nair RR, Avila H, Ma X, Wang Z, Lennartz M, Darnay BG, Boyd DD, Yan C. A novel high-throughput screening system identifies a small molecule repressive for matrix metalloproteinase-9 expression. Mol Pharmacol. 2008 Mar; 73(3):919-29. PMID: 18065684.
      View in: PubMed
    20. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007 Apr; 211(1):19-26. PMID: 17167774.
      View in: PubMed
    21. Qi W, Wu H, Yang L, Boyd DD, Wang Z. A novel function of caspase-8 in the regulation of androgen-receptor-driven gene expression. EMBO J. 2007 Jan 10; 26(1):65-75. PMID: 17170703.
      View in: PubMed
    22. Wang H, Yan C, Asangani I, Allgayer H, Boyd DD. Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression. Oncogene. 2007 Mar 29; 26(14):2058-70. PMID: 17001307.
      View in: PubMed
    23. Yan C, Boyd DD. Histone H3 acetylation and H3 K4 methylation define distinct chromatin regions permissive for transgene expression. Mol Cell Biol. 2006 Sep; 26(17):6357-71. PMID: 16914722; PMCID: PMC1592829.
    24. Yang L, Avila H, Wang H, Trevino J, Gallick GE, Kitadai Y, Sasaki T, Boyd DD. Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density--implications in tumor progression. Cancer Res. 2006 Aug 15; 66(16):7957-67. PMID: 16912170.
      View in: PubMed
    25. Nair RR, Solway J, Boyd DD. Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression. J Biol Chem. 2006 Sep 8; 281(36):26424-36. PMID: 16835221.
      View in: PubMed
    26. Yan C, Boyd DD. ATF3 regulates the stability of p53: a link to cancer. Cell Cycle. 2006 May; 5(9):926-9. PMID: 16628010.
      View in: PubMed
    27. Nair RR, Boyd DD. Expression cloning of novel regulators of 92 kDa type IV collagenase expression. Biochem Soc Trans. 2005 Nov; 33(Pt 5):1135-6. PMID: 16246065.
      View in: PubMed
    28. Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res. 2005 Sep 1; 65(17):7775-81. PMID: 16140945.
      View in: PubMed
    29. Yan C, Lu D, Hai T, Boyd DD. Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. EMBO J. 2005 Jul 6; 24(13):2425-35. PMID: 15933712; PMCID: PMC1173153.
    30. Yan C, Jamaluddin MS, Aggarwal B, Myers J, Boyd DD. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther. 2005 Feb; 4(2):233-41. PMID: 15713895.
      View in: PubMed
    31. Nair RR, Wang H, Jamaluddin MS, Fokt I, Priebe W, Boyd DD. A bisanthracycline (WP631) represses uPAR gene expression and cell migration of RKO colon cancer cells by interfering with transcription factor binding to a chromatin-accessible -148/-124 promoter region. Oncol Res. 2005; 15(5):265-79. PMID: 16261846.
      View in: PubMed
    32. Borgatti M, Boyd DD, Lampronti I, Bianchi N, Fabbri E, Saviano M, Romanelli A, Pedone C, Gambari R. Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter. Oncol Res. 2005; 15(7-8):373-83. PMID: 16491955.
      View in: PubMed
    33. Hill DA, Chiosea S, Jamaluddin S, Roy K, Fischer AH, Boyd DD, Nickerson JA, Imbalzano AN. Inducible changes in cell size and attachment area due to expression of a mutant SWI/SNF chromatin remodeling enzyme. J Cell Sci. 2004 Nov 15; 117(Pt 24):5847-54. PMID: 15537831.
      View in: PubMed
    34. Boyd DD, Nakajima M. Involvement of heparanase in tumor metastases: a new target in cancer therapy? J Natl Cancer Inst. 2004 Aug 18; 96(16):1194-5. PMID: 15316047.
      View in: PubMed
    35. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem. 2004 Sep 17; 279(38):39541-54. PMID: 15252041.
      View in: PubMed
    36. Wang H, Yang L, Jamaluddin MS, Boyd DD. The Kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells. J Biol Chem. 2004 May 21; 279(21):22674-83. PMID: 15031282.
      View in: PubMed
    37. Boyd DD, Wang H, Avila H, Parikh NU, Kessler H, Magdolen V, Gallick GE. Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness. Clin Cancer Res. 2004 Feb 15; 10(4):1545-55. PMID: 14977859.
      View in: PubMed
    38. Yan C, Wang H, Aggarwal B, Boyd DD. A novel homologous recombination system to study 92 kDa type IV collagenase transcription demonstrates that the NF-kappaB motif drives the transition from a repressed to an activated state of gene expression. FASEB J. 2004 Mar; 18(3):540-1. PMID: 14715692.
      View in: PubMed
    39. Wang H, Hicks J, Khanbolooki P, Kim SJ, Yan C, Wang Y, Boyd D. Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene. Am J Pathol. 2003 Aug; 163(2):453-64. PMID: 12875967.
      View in: PubMed
    40. Schewe DM, Leupold JH, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Schildberg FW, Jauch KW, Allgayer H. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. Clin Cancer Res. 2003 Jun; 9(6):2267-76. PMID: 12796395.
      View in: PubMed
    41. Boyd DD, Kim SJ, Wang H, Jones TR, Gallick GE. A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am J Pathol. 2003 Feb; 162(2):619-26. PMID: 12547719.
      View in: PubMed
    42. Semere WG, Edwards TM, Boyd D, Barsoumian R, Murero M, Donias HW, Karamanoukian HL. The world wide web and robotic heart surgery. Heart Surg Forum. 2003; 6(6):E111-9. PMID: 14721995.
      View in: PubMed
    43. Yan C, Wang H, Toh Y, Boyd DD. Repression of 92-kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism, which is both dependent on and independent of histone deacetylation. J Biol Chem. 2003 Jan 24; 278(4):2309-16. PMID: 12431981.
      View in: PubMed
    44. Lakka SS, Jasti SL, Gondi C, Boyd D, Chandrasekar N, Dinh DH, Olivero WC, Gujrati M, Rao JS. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene. 2002 Aug 15; 21(36):5601-8. PMID: 12165859.
      View in: PubMed
    45. Sancéau J, Boyd DD, Seiki M, Bauvois B. Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B. J Biol Chem. 2002 Sep 20; 277(38):35766-75. PMID: 12105194.
      View in: PubMed
    46. Shin M, Yan C, Boyd D. An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta. 2002 May 8; 1589(3):311-6. PMID: 12031798.
      View in: PubMed
    47. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. 2002 Jan 15; 94(2):344-51. PMID: 11900220.
      View in: PubMed
    48. Yan C, Wang H, Boyd DD. ATF3 represses 72-kDa type IV collagenase (MMP-2) expression by antagonizing p53-dependent trans-activation of the collagenase promoter. J Biol Chem. 2002 Mar 29; 277(13):10804-12. PMID: 11792711.
      View in: PubMed
    49. Bhattacharya A, Lakka SS, Mohanam S, Boyd D, Rao JS. Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines. Clin Cancer Res. 2001 Feb; 7(2):267-76. PMID: 11234878.
      View in: PubMed
    50. Yan C, Wang H, Boyd DD. KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of Ikappa Balpha -induced block of p65/p50 nuclear translocation. J Biol Chem. 2001 Jan 12; 276(2):1164-72. PMID: 11060311.
      View in: PubMed
    51. Lakka SS, Bhattacharya A, Mohanam S, Boyd D, Rao JS. Regulation of the uPA gene in various grades of human glioma cells. Int J Oncol. 2001 Jan; 18(1):71-9. PMID: 11115541.
      View in: PubMed
    52. Mazumdar A, Adam L, Boyd D, Kumar R. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion. Cancer Res. 2001 Jan 1; 61(1):400-5. PMID: 11196194.
      View in: PubMed
    53. Wang Y, Dang J, Wang H, Allgayer H, Murrell GA, Boyd D. Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem. 2000 Jun; 267(11):3248-54. PMID: 10824110.
      View in: PubMed
    54. Fang X, Yu S, Eder A, Mao M, Bast RC, Boyd D, Mills GB. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene. 1999 Nov 18; 18(48):6635-40. PMID: 10597268.
      View in: PubMed
    55. Dang J, Boyd D, Wang H, Allgayer H, Doe WF, Wang Y. A region between -141 and -61 bp containing a proximal AP-1 is essential for constitutive expression of urokinase-type plasminogen activator receptor. Eur J Biochem. 1999 Aug; 264(1):92-9. PMID: 10447677.
      View in: PubMed
    56. Allgayer H, Wang H, Shirasawa S, Sasazuki T, Boyd D. Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. Br J Cancer. 1999 Aug; 80(12):1884-91. PMID: 10471035; PMCID: PMC2363146.
    57. Simon C, Hicks MJ, Nemechek AJ, Mehta R, O'Malley BW, Goepfert H, Flaitz CM, Boyd D. PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma. Br J Cancer. 1999 Jul; 80(9):1412-9. PMID: 10424744; PMCID: PMC2363077.
    58. Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, Boyd D, Nicolson G, Montana S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci. 1999 Jun 30; 878:212-27. PMID: 10415733.
      View in: PubMed
    59. Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T, Kraker AJ, Boyd DD. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J Biol Chem. 1999 Jun 25; 274(26):18428-37. PMID: 10373450.
      View in: PubMed
    60. Allgayer H, Wang H, Wang Y, Heiss MM, Bauer R, Nyormoi O, Boyd D. Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2alpha-related factor. J Biol Chem. 1999 Feb 19; 274(8):4702-14. PMID: 9988707.
      View in: PubMed
    61. Simon C, Nemechek AJ, Boyd D, O'Malley BW, Goepfert H, Flaitz CM, Hicks MJ. An orthotopic floor-of-mouth cancer model allows quantification of tumor invasion. Laryngoscope. 1998 Nov; 108(11 Pt 1):1686-91. PMID: 9818827.
      View in: PubMed
    62. Gum R, Juarez J, Allgayer H, Mazar A, Wang Y, Boyd D. Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules. Oncogene. 1998 Jul 16; 17(2):213-25. PMID: 9674706.
      View in: PubMed
    63. Simon C, Goepfert H, Boyd D. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res. 1998 Mar 15; 58(6):1135-9. PMID: 9515796.
      View in: PubMed
    64. Nicolson GL, Nakajima M, Wakabayashi H, Boyd DD, Diaz D, Irimura T. Cancer cell heparanase activity associated with invasion and metastasis. Adv Enzyme Regul. 1998; 38:19-32. PMID: 9762344.
      View in: PubMed
    65. Gohji K, Nakajima M, Boyd D, Dinney CP, Bucana CD, Kitazana S, Kamidono S, Fidler IJ. Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells. Am J Pathol. 1997 Dec; 151(6):1655-61. PMID: 9403716.
      View in: PubMed
    66. Lengyel E, Wang H, Gum R, Simon C, Wang Y, Boyd D. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. Oncogene. 1997 May 29; 14(21):2563-73. PMID: 9191056.
      View in: PubMed
    67. Gum R, Wang H, Lengyel E, Juarez J, Boyd D. Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene. 1997 Mar 27; 14(12):1481-93. PMID: 9136992.
      View in: PubMed
    68. Mohanam S, Chintala SK, Go Y, Bhattacharya A, Venkaiah B, Boyd D, Gokaslan ZL, Sawaya R, Rao JS. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene. 1997 Mar 20; 14(11):1351-9. PMID: 9178895.
      View in: PubMed
    69. Simon C, Juarez J, Nicolson GL, Boyd D. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion. Cancer Res. 1996 Dec 1; 56(23):5369-74. PMID: 8968087.
      View in: PubMed
    70. Lengyel E, Wang H, Stepp E, Juarez J, Wang Y, Doe W, Pfarr CM, Boyd D. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J Biol Chem. 1996 Sep 20; 271(38):23176-84. PMID: 8798512.
      View in: PubMed
    71. Lengyel E, Gum R, Stepp E, Juarez J, Wang H, Boyd D. Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J Cell Biochem. 1996 Jun 1; 61(3):430-43. PMID: 8761947.
      View in: PubMed
    72. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996 May 3; 271(18):10672-80. PMID: 8631874.
      View in: PubMed
    73. Boyd D. Invasion and metastasis. Cancer Metastasis Rev. 1996 Mar; 15(1):77-89. PMID: 8842480.
      View in: PubMed
    74. Lengye E, Singh B, Gum R, Nerlov C, Sabichi A, Birrer M, Boyd D. Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. Oncogene. 1995 Dec 21; 11(12):2639-48. PMID: 8545121.
      View in: PubMed
    75. Lengyel E, Stepp E, Gum R, Boyd D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem. 1995 Sep 29; 270(39):23007-12. PMID: 7559439.
      View in: PubMed
    76. Lengyel E, Klostergaard J, Boyd D. Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors. Biochim Biophys Acta. 1995 Jul 20; 1268(1):65-72. PMID: 7626664.
      View in: PubMed
    77. Gum R, Wang SW, Lengyel E, Yu D, Hung MC, Juarez J, Boyd D. Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. Anticancer Res. 1995 Jul-Aug; 15(4):1167-72. PMID: 7653995.
      View in: PubMed
    78. Wang S, Boyd D. Modulation of urokinase-type plasminogen-activator expression by the wild-type and mutated p53 tumor-suppressor gene. Int J Oncol. 1995 Jul; 7(1):143-6. PMID: 21552819.
      View in: PubMed
    79. Lengyel E, Gum R, Juarez J, Clayman G, Seiki M, Sato H, Boyd D. Induction of M(r) 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res. 1995 Feb 15; 55(4):963-7. PMID: 7850814.
      View in: PubMed
    80. Boyd DD, Nicolson GL. Mechanisms of invasion by head and neck cancers. Cancer Treat Res. 1995; 74:117-30. PMID: 7779611.
      View in: PubMed
    81. Wang H, Skibber J, Juarez J, Boyd D. Transcriptional activation of the urokinase receptor gene in invasive colon cancer. Int J Cancer. 1994 Sep 1; 58(5):650-7. PMID: 8077048.
      View in: PubMed
    82. Rao JS, Steck PA, Tofilon P, Boyd D, Ali-Osman F, Stetler-Stevenson WG, Liotta LA, Sawaya R. Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. J Neurooncol. 1994; 18(2):129-38. PMID: 7964975.
      View in: PubMed
    83. Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D, Rao JS. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 1993 Sep 15; 53(18):4143-7. PMID: 8395977.
      View in: PubMed
    84. Juarez J, Clayman G, Nakajima M, Tanabe KK, Saya H, Nicolson GL, Boyd D. Role and regulation of expression of 92-kDa type-IV collagenase (MMP-9) in 2 invasive squamous-cell-carcinoma cell lines of the oral cavity. Int J Cancer. 1993 Aug 19; 55(1):10-8. PMID: 7688350.
      View in: PubMed
    85. Karikó K, Kuo A, Boyd D, Okada SS, Cines DB, Barnathan ES. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res. 1993 Jul 1; 53(13):3109-17. PMID: 8391387.
      View in: PubMed
    86. Clayman G, Wang SW, Nicolson GL, el-Naggar A, Mazar A, Henkin J, Blasi F, Goepfert H, Boyd DD. Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity. Int J Cancer. 1993 Apr 22; 54(1):73-80. PMID: 8386710.
      View in: PubMed
    87. Hollas W, Hoosein N, Chung LW, Mazar A, Henkin J, Kariko K, Barnathan ES, Boyd D. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb Haemost. 1992 Dec 7; 68(6):662-6. PMID: 1337629.
      View in: PubMed
    88. Hollas W, Soravia E, Mazar A, Henkin J, Blasi F, Boyd D. Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line. Biochem J. 1992 Jul 15; 285 ( Pt 2):629-34. PMID: 1322138.
      View in: PubMed
    89. Hollas W, Boyd D. Regulation of the urokinase receptor by its plasminogen activator. Thromb Haemost. 1991 Dec 2; 66(6):678-83. PMID: 1665597.
      View in: PubMed
    90. Hoosein NM, Boyd DD, Hollas WJ, Mazar A, Henkin J, Chung LW. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun. 1991 Aug; 3(8):255-64. PMID: 1653586.
      View in: PubMed
    91. Hollas W, Blasi F, Boyd D. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res. 1991 Jul 15; 51(14):3690-5. PMID: 1648443.
      View in: PubMed
    92. Hollas W, Boyd D. Urokinase-dependent proteolysis in cultured colon cancer is directed by its receptor. Semin Thromb Hemost. 1991 Jul; 17(3):225-30. PMID: 1665585.
      View in: PubMed
    93. Schlechte W, Brattain M, Boyd D. Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display. Cancer Commun. 1990; 2(5):173-9. PMID: 2164413.
      View in: PubMed
    94. Schlechte JW, Boyd DD. Insensitivity of laminin degradation directed by receptor bound urokinase to PAI-1 in cultured colon cancer. Cancer Commun. 1990; 2(8):261-9. PMID: 2390419.
      View in: PubMed
    95. Schlechte W, Murano G, Boyd D. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res. 1989 Nov 1; 49(21):6064-9. PMID: 2551498.
      View in: PubMed
    96. Boyd D. Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line. Cancer Res. 1989 May 1; 49(9):2427-32. PMID: 2539903.
      View in: PubMed
    97. Boyd D, Brattain M. Determination of the effects of epidermal growth factor on urokinase secretion and urokinase receptor display in a well-differentiated human colon carcinoma cell line. Cancer Res. 1989 Apr 15; 49(8):1948-53. PMID: 2539250.
      View in: PubMed
    98. Boyd D, Ziober B, Chakrabarty S, Brattain M. Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma. Cancer Res. 1989 Feb 15; 49(4):816-20. PMID: 2912554.
      View in: PubMed
    99. Boyd D, Florent G, Childress-Fields K, Brattain MG. Alteration in the behavior of a colon carcinoma cell line by extracellular matrix components. Cancer Lett. 1988 Jul; 41(1):81-90. PMID: 3164644.
      View in: PubMed
    100. Boyd D, Florent G, Murano G, Brattain M. Modulation of the urokinase receptor in human colon cell lines by N,N-dimethylformamide. Biochim Biophys Acta. 1988 Jun 8; 970(1):96-100. PMID: 2835992.
      View in: PubMed
    101. Boyd D, Florent G, Kim P, Brattain M. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res. 1988 Jun 1; 48(11):3112-6. PMID: 2835152.
      View in: PubMed
    102. Boyd D, Florent G, Chakrabarty S, Brattain D, Brattain MG. Alterations of the biological characteristics of a colon carcinoma cell line by colon-derived substrata material. Cancer Res. 1988 May 15; 48(10):2825-31. PMID: 3162826.
      View in: PubMed
    103. Boyd DD, Levine AE, Brattain DE, McKnight MK, Brattain MG. Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose. Cancer Res. 1988 May 1; 48(9):2469-74. PMID: 3281751.
      View in: PubMed
    104. Boyd D, Bialoski S, Brattain MG. The specific binding of transferrin to the murine fibroblast cell lines AKR-2B and its malignant counterpart AKR-MCA may be related to the transformed state. Cancer Lett. 1987 Sep; 36(3):263-71. PMID: 3652028.
      View in: PubMed
    105. Boyd D, Bialoski S, Brattain MG. Effects of difluoromethylornithine and dicyclohexylammonium sulfate on the transformed state of AKR-MCA cells. Cancer Res. 1987 Aug 1; 47(15):4099-104. PMID: 3111681.
      View in: PubMed
    106. Should Charity Air Medical Organizations Require Commercial Certification of Their Pilots?. Air Medical Journal. 34:188-194.
    107. Head and neck. Head and Neck. 23:1021-1023.
    108. Modulation of urokinase-type plasminogen activator expression by the wild-type and mutated p53 tumor suppressor gene. International Journal of Oncology. 7:143-146.
    109. First clinical evidence of a combined AP-2/Sp1 promoter motif as a tumor-specific activator of urokinase-receptor (u-PAR) expression in resected gastreintestinal cancers. European Journal of Cancer. 37.
    110. Plasminogen dependent laminin degradation and matrigel invasion by cultured colon cancer is directed by receptor-bound urokinase. Fibrinolysis and Proteolysis. 6:17-21.
    111. Divergent effect of n,n-dimethylformamide on the expression of urokinase and its receptor. Fibrinolysis and Proteolysis. 7:149-157.
    112. General aviation accidents related to exceedance of airplane weight/center of gravity limits. Accident Analysis and Prevention. 91:19-23.
    BOYD's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description